Sian Bigora - 30 Sep 2022 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Chief Development Officer
Signature
/s/ Sian Bigora by Michael B. Kirwan, as Attorney-in-Fact
Issuer symbol
PCSA
Transactions as of
30 Sep 2022
Net transactions value
$0
Form type
4
Filing time
03 Oct 2022, 16:55:34 UTC
Previous filing
09 Aug 2022
Next filing
04 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 +13,850 +4.2% $0.000000 342,227 30 Sep 2022 Common Stock 13,850 $0.000000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.